376270 — HEM Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- KR₩144bn
- KR₩140bn
- KR₩15bn
Annual cashflow statement for HEM Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | — | -13,009 | -11,667 | -7,646 |
| Depreciation | ||||
| Amortisation | ||||
| Non-Cash Items | — | 1,295 | 4,132 | 1,343 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -7,540 | -1,864 | -186 | -3,798 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | -7,540 | -11,131 | -5,269 | -7,680 |
| Capital Expenditures | -7,188 | -10,270 | -4,541 | -4,798 |
| Purchase of Fixed Assets | ||||
| Purchase / Acquisition of Intangibles | ||||
| Other Investing Cash Flow Items | -2,883 | -6,507 | 16,815 | -4,675 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -10,071 | -16,777 | 12,274 | -9,473 |
| Financing Cash Flow Items | -2.23 | -5.12 | -3.17 | -915 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 6,999 | 19,011 | -1,014 | 15,272 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -10,602 | -8,898 | 5,991 | -1,877 |